Wagg A - Search Results

1

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).

Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Wagg A, et al. Eur Urol. 2020 Feb;77(2):211-220. doi: 10.1016/j.eururo.2019.10.002. Epub 2019 Nov 13. Eur Urol. 2020. PMID: 31733990 Free article. Clinical Trial.

2

Medical therapy for the overactive bladder in the elderly.

Wagg A, Cohen M. Wagg A, et al. Age Ageing. 2002 Jul;31(4):241-6. doi: 10.1093/ageing/31.4.241. Age Ageing. 2002. PMID: 12147560 Review.

3

Overactive bladder syndrome in older people.

Wagg AS, Cardozo L, Chapple C, De Ridder D, Kelleher C, Kirby M, Milsom I, Vierhout M. Wagg AS, et al. BJU Int. 2007 Mar;99(3):502-9. doi: 10.1111/j.1464-410X.2006.06677.x. BJU Int. 2007. PMID: 17407511 Review.

4

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly.

Ulahannan D, Wagg A. Ulahannan D, et al. Among authors: wagg a. Clin Interv Aging. 2009;4:191-6. doi: 10.2147/cia.s4233. Epub 2009 May 14. Clin Interv Aging. 2009. PMID: 19503781 Free PMC article. Review.

5

Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.

Wagg A, Verdejo C, Molander U. Wagg A, et al. Int J Clin Pract. 2010 Aug;64(9):1279-86. doi: 10.1111/j.1742-1241.2010.02449.x. Epub 2010 Jun 7. Int J Clin Pract. 2010. PMID: 20529135 Review.

6

Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder.

Kraus SR, Ruiz-Cerdá JL, Martire D, Wang JT, Wagg AS. Kraus SR, et al. Urology. 2010 Dec;76(6):1350-7. doi: 10.1016/j.urology.2010.03.097. Epub 2010 Oct 25. Urology. 2010. PMID: 20974482

7

Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: a scoping review.

Hunter KF, Wagg A, Kerridge T, Chick H, Chambers T. Hunter KF, et al. Among authors: wagg a. Neurourol Urodyn. 2011 Apr;30(4):490-4. doi: 10.1002/nau.21051. Epub 2011 Jan 20. Neurourol Urodyn. 2011. PMID: 21254199 Review.

8

Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.

Wagg A, Compion G, Fahey A, Siddiqui E. Wagg A, et al. BJU Int. 2012 Dec;110(11):1767-74. doi: 10.1111/j.1464-410X.2012.11023.x. Epub 2012 Mar 12. BJU Int. 2012. PMID: 22409769

9

Antimuscarinic treatment in overactive bladder: special considerations in elderly patients.

Wagg AS. Wagg AS. Drugs Aging. 2012 Jul 1;29(7):539-48. doi: 10.1007/BF03262272. Drugs Aging. 2012. PMID: 22715861 Review.

10

Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.

Wagg A, Dale M, Tretter R, Stow B, Compion G. Wagg A, et al. Eur Urol. 2013 Jul;64(1):74-81. doi: 10.1016/j.eururo.2013.01.002. Epub 2013 Jan 11. Eur Urol. 2013. PMID: 23332882 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters